A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
A phase II study to evaluate the combination of Lenalidomide and Rituximab as front line
therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large
B-cells non-Hodgkin Lymphoma.